Esperovax
Esperovax is a preclinical-stage biotechnology company developing proprietary oral mRNA and circular RNA vaccines and therapeutics using bioengineered yeast; it serves U.S. government health and biodefense agencies (BARDA, DTRA, HHS) and pursues oncology applications via strategic partnerships.
- Company typePrivate
- Founded2019
- HeadquartersPlymouth, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Esperovax does
Esperovax, Inc. is a preclinical-stage, privately-held biotechnology company founded in 2019 and headquartered at the Michigan Life Science and Innovation Center in Plymouth, Michigan, with additional lab operations at the JLABS innovation incubator in San Francisco. The company has built a workforce of 11-50 employees and is led by President and CEO Dr. Robin Robinson — the former founding Director of BARDA and former Vaccine Director at Novavax — alongside Chairman Roger Newton (co-discoverer of Lipitor and co-founder of Esperion Therapeutics, acquired by Pfizer for $1.3 billion) and co-founders David O'Hagan and Savita Nikam.
Esperovax's core offering is the proprietary Egress RD Oral Biologics Platform, which uses bioengineered baker's yeast to continuously secrete mRNA-containing enveloped virus-like particles (eVLPs) directly to the lymphoid tissue of the gut mucosa. The platform is supported by the Egress 1 protein enabling VLP secretion, the Aques Two-Phase System (ATPS) continuous purification process (≥90% VLP recoveries), and an exclusive license from the University of Michigan for yeast-based manufacturing technology; three patents are pending. The current pipeline includes an oral COVID-19 mRNA vaccine, an oral H5N1 influenza RNA vaccine (developed under DTRA), and circular RNA-based therapeutics for colorectal cancer developed in partnership with Ginkgo Bioworks. The platform is designed to produce thermostable, self-administered oral doses at scale, eliminating cold-chain requirements, syringes, and costly purification steps.
The company is pre-revenue and generates operating inflows exclusively through non-dilutive federal research contracts and grants (BARDA $607K in 2020; HHS Project NextGen $1M in 2023; DTRA $1.5M in 2024), supplemented by a state-backed investment from Michigan Rise and prospective licensing royalties. Go-to-market is directed at U.S. government health and biodefense agencies (BARDA, DTRA, HHS) and military health programs, accessed both directly and via prime contractors such as DynPort Vaccine Company (GDIT), with parallel strategic partnerships with JLABS, Ginkgo Bioworks, Life Magnetics, UTMB-Galveston, and St. Jude Children's Research Hospital supporting pre-clinical development and validation.
Esperovax firmographics
Firmographics- Name
- Esperovax
- Legal name
- Esperovax, Inc.
- Website
- https://esperovax.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Esperovax is a preclinical-stage biotechnology company developing proprietary oral mRNA and circular RNA vaccines and therapeutics using bioengineered yeast; it serves U.S. government health and biodefense agencies (BARDA, DTRA, HHS) and pursues oncology applications via strategic partnerships.
- Ownership category
- akta.pro rank
Esperovax industry classification
Industry- Product category
- Oral mRNA Vaccines and Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industries
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
Keywords
Where Esperovax is headquartered
LocationHeadquarters
- HQ city
- Plymouth
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Esperovax business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Revenue model
- Government Research Contracts and Subcontracts: Esperovax generates revenue through government contracts with BARDA, DTRA, and HHS Project NextGen Initiative. These contracts fund preclinical development, animal studies, and platform development for specific vaccine candidates (COVID-19, H5N1 influenza).
- Licensing Revenue: The company holds exclusive licensing agreements for technologies from the University of Michigan and may generate future revenue through licensing its proprietary platform technologies to pharmaceutical partners.
- Strategic Partnership Payments: Collaborations with companies like Ginkgo Bioworks and Life Magnetics may include upfront payments, milestone payments, and research funding for co-development of therapeutics.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Esperovax product offering
Product offeringCore offering
Esperovax develops a proprietary oral mRNA vaccine platform (Egress RD) that uses bioengineered probiotic baker's yeast to deliver vaccine antigens as enveloped virus-like particles (eVLPs) directly to gut lymphoid tissue via small oral capsules. The platform enables thermostable, needle-free, self-administered vaccines that can be produced at scale in weeks without cold chain, syringes, or costly purification processes. Product candidates include oral COVID-19 and H5N1 influenza RNA vaccines, as well as circular RNA-based therapeutics for oncology applications.
Product overview
Esperovax is a preclinical biopharmaceutical company developing targeted oral mRNA-based vaccines and biologics through its proprietary Egress RD™ Oral Biologics Platform. The platform uses bioengineered probiotic baker's yeast to produce and deliver continuous, highly-concentrated vaccine antigens as enveloped virus-like particles (eVLPs) directly to the lymphoid tissue of the gut mucosa. The product portfolio includes: (1) Egress RD™ Platform as the core technology foundation, (2) COVID-19 Oral mRNA Vaccine (CoV-2) targeting COVID-19 viruses, (3) Oral H5N1 Influenza RNA Vaccine for pandemic preparedness, and (4) Circular RNA-based Therapeutics for oncology applications. The technology enables production of billions of doses in weeks without cold storage or syringes, delivered as oral tablets or capsules.
Differentiator
Problem solved
Functional benefit
Products and services
- Egress RD Oral Biologics Platform Proprietary oral vaccine platform utilizing bioengineered probiotic baker's yeast to deliver continuous, highly-concentrated vaccine antigens to the gut as enveloped virus-like particles (eVLPs). The platform enables rapid production of billions of doses in weeks without costly purification, cold storage, or syringes. It is the foundation product on which all of Esperovax's vaccine candidates are built.
- Oral COVID-19 mRNA Vaccine (CoV-2) Oral COVID-19 vaccine candidate built on the Egress RD platform that delivers genetic instructions via mRNA technology to prompt the immune system to fight specific SARS-CoV-2 strains. Can be adapted quickly to tackle emerging variants and is administered as a thermostable oral capsule without syringes. Currently in pre-clinical development with government funding.
- Oral H5N1 Influenza RNA Vaccine Thermostable oral circular RNA-based H5N1 influenza vaccine candidate developed under Esperovax's proprietary yeast-based circular RNA technologies. Designed to elicit systemic and mucosal humoral and cell-mediated immunity protecting against respiratory tract viral infection in military and biodefense contexts. Currently in pre-clinical development.
- Circular RNA-based Therapeutics (Colorectal Cancer) Circular RNA therapeutic program developed in partnership with Ginkgo Bioworks, initially targeting colorectal cancer by developing circRNAs harboring payloads to specifically target cancerous cells and induce cell death. Combines Esperovax's oral RNA delivery capability with Ginkgo's cell programming capabilities.
Quantifiable outcome
- PPV and HIV VLP recoveries >=90% with majority of contaminants removed using Aques Two-Phase System purification
- +1 more outcomes
Companies that use Esperovax
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Esperovax technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Esperovax partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- DynPort Vaccine Company LLC (DVC)coreTwo-year base subcontract valued at $1.5 million for pre-clinical development of oral H5N1 influenza RNA vaccine. DVC, a GDIT company, manages the project while Esperovax provides technical expertise and R&D capabilities under DTRA's Medical CBRN Defense Consortium.
- St. Jude Children's Research HospitalcoreDr. Richard Webby at St. Jude is part of the team committed to advancing the novel H5N1 oral vaccine platform with robust and long-lasting protective immunity.
- University of Texas Medical Branch - GalvestoncoreCollaboration with Dr. Slobodan Paessler at UTMB to conduct animal challenge studies demonstrating vaccine safety and immunoprotection in orally vaccinated animals challenged with different COVID-19 virus variants.
- Ginkgo BioworkscorePartnership to develop circular RNAs for therapeutic applications. Initially targeting colorectal cancer by developing circRNAs harboring payloads to specifically target cancerous cells and induce cell death. Combines Esperovax's oral RNA delivery with Ginkgo's cell programming capabilities.
- University of MichigancoreExclusive licensing agreement for novel yeast-based manufacturing technology for production of vaccines and therapeutics. The agreement enables continuous purification process with higher yields at optimal cost. The University also received right to invest in Esperovax's capital raise and future rounds.
- Johnson & Johnson Innovation - JLABScoreBlue Knight is a joint initiative between JLABS and BARDA dedicated to anticipating health security threats. Esperovax selected as a Blue Knight company, gaining access to JLABS global innovation network incubator in San Francisco and continuing engagement with JLABS and BARDA for research acceleration.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Esperovax competitors and assessment
Company assessmentDirect peers
- Vaxart: Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines in tablet form. It is the closest direct competitor to Esperovax, sharing the oral vaccine delivery thesis, focus on room-temperature stability, and target indications including COVID-19 and influenza.
- Moderna: Moderna is the leading mRNA vaccine platform company with approved COVID-19 vaccines and a broad pipeline. It is the dominant benchmark for mRNA vaccine technology, competing with Esperovax for government stockpiling contracts and pandemic preparedness funding.
- BioNTech: BioNTech pioneered mRNA vaccines for COVID-19 in partnership with Pfizer and is expanding into oncology and infectious disease. It competes directly with Esperovax's mRNA platform for vaccine market share and government contracts.
- Novavax: Novavax is a commercial-stage vaccine developer with a recombinant protein nanoparticle platform, including an approved COVID-19 vaccine. It competes with Esperovax in the pandemic preparedness and influenza vaccine space; Esperovax's CEO Dr. Robinson is Novavax's former Vaccine Director.
Emerging players
- Arcturus Therapeutics: Arcturus develops self-amplifying mRNA (saRNA) vaccines and therapeutics with a focus on low-dose, long-lasting immunity. Its technology overlaps with Esperovax's RVLP/AVLP approach and shares the goal of reducing dose burden and improving stability.
- Translate Bio (acquired by Sanofi): Translate Bio was an mRNA therapeutics platform company acquired by Sanofi in 2021 for its lipid nanoparticle delivery technology. It represented a comparable mRNA platform play with pharma partnership exit, providing a benchmark exit path for Esperovax.
Broad incumbents
- Sanofi Pasteur: Sanofi Pasteur is one of the world's largest vaccine manufacturers with broad portfolio across influenza, pediatric, and travel vaccines. It is a likely strategic acquirer or large-pharma partner for Esperovax's oral platform technology.
- Pfizer: Pfizer is the largest vaccine company globally through its COVID-19 partnership with BioNTech and broad infectious disease portfolio. It is a credible strategic acquirer; founder Roger Newton's prior company Esperion was acquired by Pfizer for $1.3B.
Others
- Ginkgo Bioworks: Ginkgo Bioworks is a cell programming and synthetic biology platform company. Esperovax has an active partnership with Ginkgo to co-develop circular RNA therapeutics for colorectal cancer, making Ginkgo both a peer in cell-based therapeutics and an active partner.
- PharmaJet: PharmaJet develops needle-free injection devices for vaccine and drug delivery, addressing the same needle-free administration pain point as Esperovax. It is comparable as an enabling technology provider in the needle-free vaccine delivery ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Esperovax social profiles
Digital presenceEsperovax financial estimates
Financial estimateRevenue estimate
Valuation estimate
Esperovax leadership team
Management profileNumber of profiles
Profiles6 records
Esperovax funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Esperovax M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Esperovax
What does Esperovax do?
Esperovax develops a proprietary oral mRNA vaccine platform (Egress RD) that uses bioengineered probiotic baker's yeast to deliver vaccine antigens as enveloped virus-like particles (eVLPs) directly to gut lymphoid tissue via small oral capsules. The platform enables thermostable, needle-free, self-administered vaccines that can be produced at scale in weeks without cold chain, syringes, or costly purification processes. Product candidates include oral COVID-19 and H5N1 influenza RNA vaccines, as well as circular RNA-based therapeutics for oncology applications.
Is Esperovax a public or private company?
Esperovax is a private company. It is classified as venture growth investor backed and is currently operating.
When was Esperovax founded?
Esperovax was founded in 2019. It employs 11 to 50 people.
Where is Esperovax based?
Esperovax is headquartered in Plymouth, United States, in the North America region.
How does Esperovax make money?
Three revenue lines are on record. Government Research Contracts and Subcontracts are the primary driver. The others are licensing Revenue and strategic Partnership Payments.
Who are Esperovax's main competitors?
Direct peers on record are Vaxart, Moderna, BioNTech and Novavax. Emerging players are Arcturus Therapeutics and Translate Bio (acquired by Sanofi). Broad incumbents are Sanofi Pasteur and Pfizer. Others are Ginkgo Bioworks and PharmaJet.
Does Esperovax have an API?
No public API is recorded for Esperovax.
What industry is Esperovax in?
Esperovax's product category is Oral mRNA Vaccines and Biologics. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 325414 and its SIC code is 2836.